KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Amortizatization of Intangibles (2018 - 2023)

Historic Amortizatization of Intangibles for Esperion Therapeutics (ESPR) over the last 6 years, with Q2 2023 value amounting to $73000.0.

  • Esperion Therapeutics' Amortizatization of Intangibles rose 13668.34% to $73000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $73000.0, marking a year-over-year decrease of 6866.95%. This contributed to the annual value of $412000.0 for FY2023, which is 24767.03% up from last year.
  • According to the latest figures from Q2 2023, Esperion Therapeutics' Amortizatization of Intangibles is $73000.0, which was up 13668.34% from $339000.0 recorded in Q1 2023.
  • Esperion Therapeutics' Amortizatization of Intangibles' 5-year high stood at $339000.0 during Q1 2023, with a 5-year trough of -$199000.0 in Q2 2022.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $33000.0 (2019), whereas its average is $29857.1.
  • In the last 5 years, Esperion Therapeutics' Amortizatization of Intangibles crashed by 7894.74% in 2020 and then skyrocketed by 226666.67% in 2022.
  • Esperion Therapeutics' Amortizatization of Intangibles (Quarter) stood at $60000.0 in 2019, then plummeted by 93.33% to $4000.0 in 2020, then plummeted by 400.0% to -$12000.0 in 2021, then surged by 2266.67% to $260000.0 in 2022, then plummeted by 71.92% to $73000.0 in 2023.
  • Its Amortizatization of Intangibles stands at $73000.0 for Q2 2023, versus $339000.0 for Q1 2023 and $260000.0 for Q4 2022.